Table 5.
Published reproductive and oncologic outcomes after FST of STUMP and LMS.
| Study, Year [Ref] | Design | FST Patients (n) |
Age (Median, Range) |
Parity | Surgery | Adjuvant Treatment | Follow Up (Median, Range) |
Recurrence, n (%) | Death, n (%) | Total Pregnancies (n) | ART (n) |
Details |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ning, 2021 [19] | Retrospective | 2 (STUMP) |
36 (34–38) |
NA | Laparoscopic myomectomy: 2 | - | 74.5 (71–78) |
0 | 0 | 2 | 0 | Full-term C-section: 2 |
| Shim, 2020 [20] | Retrospective | 48 (STUMP) |
32.5 (20–46) |
NU: 44; PS: 4 | Myomectomy: 48 | - | 28.5 (7–130) |
3 (6.3) | 0 | 16 | 6 | Full-term C-section: 10; Ongoing: 4; First trimester miscarriage: 2 |
| Tunc, 2019 [11] | Retrospective | 13 (LG-ESS: 6; LMS: 7) |
28 (23–37) |
NU: 4; PS: 3 | Excision of mass: 3; excision of mass + staging surgery: 4 | CT (IFO + ACNU): 3 No: 4 |
31 (16–109) |
5 (71.4) | 4 (57.1) |
3 | 1 | Full-term C-section: 2; preterm C-section (28 W): 1. Recurrence during pregnancy: 1 |
| Şahin, 2019 [21] | Retrospective | 27 (STUMP) |
37 (23–52) |
0 (0–3) | Laparotomic myomectomy: 26; hysteroscopic myomectomy: 1 | - | 58 (16–125) |
6 (22.2) | 1 (3.7) |
7 | 3 | Full-term C-section: 5; preterm C-section (35 W): 1; full-term VB: 1 |
| Ha, 2018 [22] | Retrospective | 7 (STUMP) |
32 (28–48) |
NU 6; PS 1 | Myomectomy: 7 | - | NA | 0 | 0 | 4 | 3 | Full-term C-section: 3, ongoing: 1 |
ART: assisted reproductive technology; ACNU: nimustine; C-section: caesarean section; CT: chemotherapy; FST: fertility-sparing treatment; IFO: ifosfamide; LG-ESS: low-grade endometrial stromal sarcoma; LMS: leiomyosarcoma; n: number; NA: not available; NU: nulliparous; PS: parous; STUMP: smooth muscle tumor of uncertain malignant potential; VB: vaginal birth; W: weeks.